Clinical Trial Update: A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 study comparing Ociperlimab plus Tislelizumab vs Durvalumab after concurrent chemoradiotherapy in stage III unresectable non-small cell lung cancer was …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Ociperlimab (ociperlimab)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: BeiGene | Conditions: Non Small Cell Lung Cancer | Phase 3 | Status: TERMINATED | Results posted: 2024-10-31